Clinical Trial Update: Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) [Phase 2]

View source ↗

Summary

Phase 2 trial SEGNO is exploring genomic biomarker-guided neoadjuvant therapy for locally advanced or oligometastatic prostate cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oligometastatic Prostate Cancer
• Prostate Cancer

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer | Phase 2 | Status: RECRUITING